SG11202005112TA - Heterocyclic compounds as prmt5 inhibitors - Google Patents
Heterocyclic compounds as prmt5 inhibitorsInfo
- Publication number
- SG11202005112TA SG11202005112TA SG11202005112TA SG11202005112TA SG11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- prmt5 inhibitors
- prmt5
- inhibitors
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594898P | 2017-12-05 | 2017-12-05 | |
PCT/US2018/058721 WO2019112719A1 (en) | 2017-12-05 | 2018-11-01 | Heterocyclic compounds as prmt5 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005112TA true SG11202005112TA (en) | 2020-06-29 |
Family
ID=66750587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005112TA SG11202005112TA (en) | 2017-12-05 | 2018-11-01 | Heterocyclic compounds as prmt5 inhibitors |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200369667A1 (en) |
EP (1) | EP3720495A4 (en) |
JP (1) | JP2021505583A (en) |
KR (1) | KR20200096265A (en) |
CN (1) | CN111741964A (en) |
AU (1) | AU2018381004B2 (en) |
CA (1) | CA3084253A1 (en) |
SG (1) | SG11202005112TA (en) |
WO (1) | WO2019112719A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
CN114072407A (en) * | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | Compounds targeting PRMT5 |
CN114126614A (en) * | 2019-05-30 | 2022-03-01 | 安杰斯制药公司 | Heterocyclic compounds as PRMT5 inhibitors |
WO2021079196A2 (en) * | 2019-10-21 | 2021-04-29 | Accent Therapeutics, Inc | Mettl3 modulators |
CN116568677A (en) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers |
CN113234079B (en) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | Nucleoside analogs as PRMT5 inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013013659B8 (en) * | 2010-12-03 | 2024-02-27 | Epizyme Inc | Epigenetic enzyme modulating compounds, pharmaceutical composition comprising said compounds and uses of said pharmaceutical composition for treating cancer, hematological cancer or leukemia |
BR112013013668A2 (en) * | 2010-12-03 | 2016-09-06 | Epizyme Inc | 7-deazapurine histone methyltransferase modulators, and methods of using them |
TWI730980B (en) * | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
EP3426664B1 (en) * | 2016-03-10 | 2021-06-30 | Janssen Pharmaceutica NV | Substituted nucleoside analogues for use as prmt5 inhibitors |
CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
GB201700526D0 (en) * | 2017-01-12 | 2017-03-01 | Univ Of Hull | Therapeutic use |
US11220524B2 (en) * | 2017-02-20 | 2022-01-11 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
MX2019010150A (en) * | 2017-02-27 | 2019-10-21 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor. |
WO2018160855A1 (en) * | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018160824A1 (en) * | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
GB201709406D0 (en) * | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
-
2018
- 2018-11-01 CN CN201880088513.9A patent/CN111741964A/en active Pending
- 2018-11-01 KR KR1020207018994A patent/KR20200096265A/en not_active Application Discontinuation
- 2018-11-01 SG SG11202005112TA patent/SG11202005112TA/en unknown
- 2018-11-01 US US16/767,077 patent/US20200369667A1/en not_active Abandoned
- 2018-11-01 CA CA3084253A patent/CA3084253A1/en not_active Abandoned
- 2018-11-01 EP EP18885162.0A patent/EP3720495A4/en not_active Withdrawn
- 2018-11-01 WO PCT/US2018/058721 patent/WO2019112719A1/en unknown
- 2018-11-01 JP JP2020530608A patent/JP2021505583A/en active Pending
- 2018-11-01 AU AU2018381004A patent/AU2018381004B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA3084253A1 (en) | 2019-06-13 |
KR20200096265A (en) | 2020-08-11 |
JP2021505583A (en) | 2021-02-18 |
AU2018381004B2 (en) | 2021-04-29 |
AU2018381004A1 (en) | 2020-06-18 |
EP3720495A1 (en) | 2020-10-14 |
US20200369667A1 (en) | 2020-11-26 |
EP3720495A4 (en) | 2021-06-02 |
CN111741964A (en) | 2020-10-02 |
WO2019112719A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
HK1249905A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
IL273428A (en) | Heterocyclic compounds as pad inhibitors | |
HK1245244A1 (en) | Heterocyclic amides as kinase inhibitors | |
IL269188A (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
HUE059324T2 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
IL267781A (en) | Heterocyclic spiro compounds as magl inhibitors | |
IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
EP3660003C0 (en) | Heterocyclic compound | |
EP3693360C0 (en) | Heterocyclic compounds | |
EP3693368C0 (en) | Heterocyclic compound | |
PT3643718T (en) | Heterocyclic compound | |
ZA201907792B (en) | Heterocyclic compound | |
ZA201907793B (en) | Heterocyclic compound |